中文     English
Tianjin Chase Sun Pharmaceutical Co. LTD(300026)will acquire 100% equity of Choicemmed and 100% equity of Zhanwang Pharmaceutical with 1.57 billion RMB ( US $262 million)

 

 

 

Tianjin Chase Sun Pharmaceutical Co. LTD300026intends to acquire 100% equity of Choicemmed and 100% equity of Zhanwang Pharmaceutical with 1.57 billion RMB ( US $262 million). Choicemmed focuses on developing, manufacturing, and marketing electronic healthcare products. The net profits of Choicemmed are 27,316,000 RMB (US $4,552,667) in 2013; 30,858,900RMB (US $5,143,150) in 2014; and 9,465,900 RMB (US $1,577,650) before March 2015. The main products of Zhanwang Pharmaceutical are API and pharmaceutic adjuvant, including hypromellose, hyprolose and avicel etc. The net profits of Zhanwang Pharmaceutical are 16,547,300RMB (US $2,757,883) in 2013; 11,938,200RMB (US $1,989,700) in 2014; and 3,021,000RMB (US $503,500) before March 2015.

 

For more information, please contact us at david.chen@bfcgroup.biz